KB-1399

NGM438-hIgG1

45626

Background of NGM438-hIgG1

LAIR1 is a hematopoietic lineage-restricted collagen receptor reported to regulate diverse responses across both innate and adaptive immune cell types, including activation, differentiation, and antigen recognition. NGM438, a novel humanized LAIR1 antagonist monoclonal antibody, elicits myeloid inflammation and allogeneic T cell responses by binding to LAIR1 and blocking collagen engagement.

Specifications

Catalog Number	KB-1399
Antibody Name	NGM438-hIgG1
Isotype	Human IgG1,kappa
Target	LAIR-1
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Preclinical Development of NGM438, a Novel Anti-LAIR1 Antagonist Monoclonal Antibody for the Treatment of Collagen-Rich Solid Tumors-AACR 2022 Abstract # 7571
Rodriguez BL, Huang J, Gibson L, Fradette JJ, Chen HH, Koyano K, Cortez C, Li B, Ho C, Ashique AM, Lin VY, Crawley S, Roda JM, Chen P, Fan B, Kim J, Sissons J, Sitrin J, Kaplan DD, Gibbons DL, Rivera LB. Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors. Mol Cancer Ther. 2024 Aug 1;23(8):1144-1158.